Bayforest Capital Ltd Invests $840,000 in BioCryst Pharmaceuticals, Inc. $BCRX

Bayforest Capital Ltd bought a new position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 93,722 shares of the biotechnology company’s stock, valued at approximately $840,000.

Other institutional investors have also made changes to their positions in the company. Assenagon Asset Management S.A. increased its position in shares of BioCryst Pharmaceuticals by 25,631.2% in the second quarter. Assenagon Asset Management S.A. now owns 3,620,637 shares of the biotechnology company’s stock worth $32,441,000 after acquiring an additional 3,606,566 shares in the last quarter. Doliver Advisors LP increased its position in shares of BioCryst Pharmaceuticals by 269.1% in the second quarter. Doliver Advisors LP now owns 274,328 shares of the biotechnology company’s stock worth $2,458,000 after acquiring an additional 200,000 shares in the last quarter. Acadian Asset Management LLC increased its position in shares of BioCryst Pharmaceuticals by 244.1% in the first quarter. Acadian Asset Management LLC now owns 670,361 shares of the biotechnology company’s stock worth $5,023,000 after acquiring an additional 475,564 shares in the last quarter. Millennium Management LLC increased its position in shares of BioCryst Pharmaceuticals by 382.6% in the first quarter. Millennium Management LLC now owns 3,812,874 shares of the biotechnology company’s stock worth $28,597,000 after acquiring an additional 3,022,769 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC purchased a new stake in shares of BioCryst Pharmaceuticals in the first quarter worth approximately $79,000. 85.88% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms recently commented on BCRX. Weiss Ratings restated a “sell (d-)” rating on shares of BioCryst Pharmaceuticals in a report on Wednesday, October 8th. Wedbush lifted their price objective on shares of BioCryst Pharmaceuticals from $16.00 to $18.00 and gave the company an “outperform” rating in a research note on Monday, June 30th. Bank of America lifted their price objective on shares of BioCryst Pharmaceuticals from $13.00 to $15.00 and gave the company a “buy” rating in a research note on Tuesday, July 1st. Wall Street Zen raised shares of BioCryst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, July 26th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $17.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Monday, August 4th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $16.30.

Insider Buying and Selling

In related news, Director Theresa Heggie sold 70,000 shares of the company’s stock in a transaction on Wednesday, August 13th. The shares were sold at an average price of $8.51, for a total transaction of $595,700.00. Following the completion of the transaction, the director directly owned 65,352 shares in the company, valued at $556,145.52. This represents a 51.72% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 5.10% of the stock is currently owned by insiders.

BioCryst Pharmaceuticals Trading Down 2.5%

NASDAQ BCRX opened at $7.04 on Tuesday. The company has a fifty day simple moving average of $7.98 and a 200 day simple moving average of $8.68. The company has a market cap of $1.48 billion, a P/E ratio of -39.11, a P/E/G ratio of 1.45 and a beta of 1.05. BioCryst Pharmaceuticals, Inc. has a 1 year low of $6.01 and a 1 year high of $11.31.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings data on Monday, August 4th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.03 by $0.12. The firm had revenue of $163.35 million for the quarter, compared to the consensus estimate of $149.59 million. BioCryst Pharmaceuticals’s quarterly revenue was up 49.5% on a year-over-year basis. During the same period in the prior year, the company posted ($0.06) earnings per share. Equities research analysts forecast that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current fiscal year.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.